Abstract
Eicosanoids are metabolic products derived from polyunsaturated straight-chain C 20 carboxylic acids. The most abundant substrate in humans is arachidonic acid (AA), a physiological component of the plasma membrane. Following stimulation, AA is released from an ester linkage to phospholipids and oxygenated into an array of compounds whose biological importance has been well established in vitro. On the other hand, the investigation of their potential role in human pathology depends upon assessment of their formation in vivo. Alterations in eicosanoid biosynthesis in pathological conditions and the functional consequences of their pharmacological inhibition or antagonism have indicated their pathophysiological role in vivo1–5. Specific and sensitive assays for eicosanoids have been required to address these issues.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fitzgerald, D.J., Roy L., Catella, F., and FitzGerald, G.A. Platelet activation in unstable coronary disease. N. Eng. J. Med.; 315: 983–989, (1986).
Lewis, H.D., Davis, J.W., Archibald, D.G., et. al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N. Eng. J. Mcd.; 309: 396–403, (1983).
Cairns, J.A., Gent, M., Singer, J., et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N. Eng. J. Med. 313: 1369–75, (1985).
Fitzgerald, D.J., Catella, F., Roy, L. and FitzGerald, G.A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation; 77 (1): 142–150 (1988).
ISIS-2(Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet; i: 349–360, (1988).
Parry, M.J., Randall, M.J., Tyler, H.M., Myhre, E., Dabe, J. and Thaulow, E. Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leukocytes in angina patients and healthy volunteers. Lancet; ii;164, (1982) (letter).
Pedersen, A.K., Watson, M.L. and FitzGerald, G.A. Limitations of the measurement of immunoreactive 6-keto-PGF1a. Thromb. Res.; 33: 99–103, (1983).
Ciabattoni, G., Maclouf, J., Catella, F., FitzGerald, G.A., and Patrono, C. Radioimmunoassay of 11-dehydrothromboxane B 2 in human plasma and urine. Biochim. Biophys. Acta.; 918: 293–7, (1987).
Patrono, C., Ciabattoni, G., Pugliese, F., Pierucci, A., Blair, I.A., and FitzGerald, G.A. Estimated rate of thromboxane secretion into the circulation of normal humans. J. Clin. Invest.; 77: 590–94, (1986).
Knapp, H.R., Reilly, I.A.G., Alessandrini, P. and FitzGerald, G.A. In vivo indexes of platelet and vascular functions during fish-oil administration in patients with atherosclerosis. N. Eng. J. Med., 324:937–942, (1986).
Needleman, P., Raz, A., Minkes, M.S., Ferrendelli, J.A., and Sprecher, H. Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties. Proc. Natl. Acad. Sci. USA 76: 944–948, (1979).
Braden, G.A., Fitzgerald, D.J., Knapp, H.R. and FitzGerald, G.A. Increased thromboxane (Tx)A2 biosynthesis during coronary thrombosis and thrombolysis with n-3 fatty acid (FA) supplementation. Circulation; 78 (4); II - 120, (1988).
Catella, F., Healy D., Lawson, J.A. and FitzGerald G.A. 11- Dehydrothromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. Proc. Natl. Acad. Sci, USA; 83: 5861–65, (1986).
Catella, F. and FitzGerald, G.A. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb. Res.; 47: 647–656, (1987).
Falardeau, P., Oates, J.A. and Brash, A.R. Quantitative analysis of two dinor urinary metabolites of prostaglandin I2. Anal. Biochem.; 115: 359–67, (1981).
Lawson, J.A., Brash, A.R., Doran, J. and FitzGerald, G.A. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography-negative-ion chemical ionization mass spectrometry. Anal. Biochem. 150: 463–470, (1985).
Hubbard, H.L., Eller, T.D., Mais, D.E., Halushka, P.V., Baker, R.H., Blair, I.A., Vrbanac, J.J., and Knapp, D.R. Extraction of thromboxane B2 from urine using an immobilized antibody column for subsequent analysis by gas chromatography-mass spectometry. Prostaglandins; 33: 149, 1987.
Brash, A.R., Baillie, T.A., Claire, R.A., and Draffan, G.H. Quantitative determination of the major metabolite of prostaglandins F1 and F2 in human urine by stable isotope dilution and combined gas chromatography-mass spectrometry. Biochem. Med. 16: 77–94, (1976).
Whittaker, N. Tetrahedron Lett. A synthesis of prostacyclin sodium salt. 32: 2805–3808, (1977).
Sun, F.F., Taylor, B.M., Lincoln, F.H., and Sebek, O.K. Preparation of two dinor-PGI2 metabolites from 6-keto-PGF1a by mycobacterium rhodochrous. Prostaglandins 20: 729–734, (1980).
Balazy, M., Brass, E.P., Gerber, J.G., and Nies, A.S. Facile method for preparation of 2,3-dinor-6-keto PGF1, the major urinary metabolite of prostacyclin. Prostaglandins; 36: 421–43%, 1988.
Lawson, J.A., Patrono, C., Ciabattoni, G., and FitzGerald, G.A. Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. Anal. Biochem. 155: 198–205, (1986).
Blair, I.A., Barrow, S.E., Waddell, K.A., Lewis, P.J., and Dollery, C.T. Prostacyclin is not a circulating hormone in man. Prostaglandins; 23: 579589, (1982).
FitzGerald, G.A., Brash, A.R. Falardeau, P., and Oates, J.A. Estimated rate of prostacyclin secretion into the circulation of normal man. J. Clin. Invest. 68: 1271–76, (1981).
Neri Serneri, G.G., Gensini, F.F., Abbate, R., et al. Abnormal cardio- coronary thromboxane A2 production in patients with unstable angina. Am. Heart. J.; 109: 732–8, (1985).
Patrignani, P., Filabozzi P., and Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69: 1366–72, (1982).
Patrono, C., Ciabattoni, G., Patrignani, P., et al. Evidence for a renal origin of urinary thromboxane B2 in health and disease. In: Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol 11, ed. by B. Samuelsson, R., Paoletti, R., and Ramwell, P.W. 493–498, Raven Press, New York, 1983.
Nowak, J., and FitzGerald, G.A.: Prostaglandin endoperoxide reorientation at the platelet vascular interface in man. J. Clin. Invest. (in press) 1988.
Dworski,R.,Sheller,J.,Wickersham, N.E.,Oates,J.A., Brigham,K.L.,Roberts,L.J.,II,FitzGerald,G.A.Allergen stimulated release of mediators into sheep bronchoalveolar lavage fluid: Effect of cyclooxygenase inhibition. Am.Rev.Res.Dis.(in press), 1989.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Plenum Press, New York
About this paper
Cite this paper
Catella, F., Johnson, J.M., FitzGerald, G.A. (1989). Quantitative Analysis of Eicosanoids by Gas Chromatography-Mass Spectrometry. In: Samuelsson, B., Berti, F., Folco, G.C., Velo, G.P. (eds) Prostanoids and Drugs. NATO ASI Series, vol 177. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-7938-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-4684-7938-6_3
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-7940-9
Online ISBN: 978-1-4684-7938-6
eBook Packages: Springer Book Archive